The Bell Law Firm Renews Investigations into Lipitor Injury Claims as...
The Charlestonbased law firm continues to investigate claims of women who developed Type II diabetes after taking the cholesterollowering drug Lipitor as 56 cases are centralized into multidistrict...
View ArticleNew study suggests combination of statin and omega3 fatty acid may provide...
Brigham and Women's Hospital New findings from an in vitro study led by researchers at Brigham and Women's Hospital show that the combination of statins and eicosapentaenoic acid an omega3 fatty acid...
View ArticleThe Medicines Company and Alnylam Announce Presentation of New PreClinical...
PARSIPPANY NJ Marketwired 050114 The Medicines Company NASDAQ MDCO and Alnylam Pharmaceuticals Inc. NASDAQ ALNY announced today the presentation of new preclinical data from ALNPCSsc targeting PCSK9...
View ArticleCatabasis Describes Modulation of SREBP as Mechanism for CAT2003
Insights on Mechanism of Action Presented at ATVB 2014 Scientific Sessions Catabasis Pharmaceuticals Inc. today announced the presentation of preclinical data demonstrating the mechanism of action for...
View ArticleAlnylam Presents New Preclinical Data on Subcutaneously Delivered RNAi...
Demonstrates Robust Durable and Clamped Knockdown of PCSK9 of up to 96 and Reduction of LDLC of up to 77 with Single Dose of ALNPCSsc in Absence of Statins in NonHuman Primates Data Support OnceMonthly...
View ArticleStatins for kidney disease patients Protection for the heart but no effects...
Lowering LDL cholesterol through statinbased treatment did not slow kidney disease progression within five years in a study appearing in an upcoming issue of the Journal of the American Society of...
View ArticleEsperion Therapeutics to Deliver Three Scientific Poster Presentations at the...
Esperion Therapeutics Inc. Nasdaq ESPR today announced the company will deliver three posters featuring ETC1002 Phase 2 clinical results at the 2014 Annual Scientific Sessions of the National Lipid...
View ArticleStatin use associated with reduced risk of prostate cancer recurrence
Medical XpressMen who begin taking statins after prostate cancer surgery are less likely to have a recurrence of their cancer according to a retrospective analysis led by researchers at Duke Medicine.
View ArticleOutcomes Study Supports Use of LDL Particle Number to Guide Statin Therapy in...
ORLANDO Fla. May 2 2014 PRNewswire LipoScience Inc. NASDAQ LPDX a diagnostic company pioneering a new field of personalized nuclear magnetic resonance NMR diagnostics to advance the quality of patient...
View ArticleThe National Lipid Association Addresses the Safety of Statins and Provides...
Expert Panel Proposes a Definition of Statin Intolerance With an estimated 15 million Americans taking a statin drug to reduce high cholesterol patients and health care providers alike are seeking more...
View ArticleStatins for kidney disease patients Protection for heart but no effects on...
For patients with chronic kidney disease statin treatment appears to lower LDL cholesterol decrease the risk of heart disease and stroke and has no impact on the development of kidney failure research...
View ArticleCVS Caremark Research Finds Eliminating Medication Copays PostHeart Attack...
WOONSOCKET R.I. May 5 2014 PRNewswire A new study by researchers at CVS Caremark NYSE CVS Aetna and Brigham and Women's Hospital published today in the May issue of Health Affairs finds that...
View ArticleFDA Approves EPANOVA for the Treatment of Adults with Severe...
WILMINGTON Del. May 6 2014 PRNewswire AstraZeneca NYSE AZN today announced the US Food and Drug Administration FDA approved EPANOVA&174; omega3carboxylic acids as an adjunct to diet to reduce...
View ArticleAAPS PharmSciTech Novel Simvastatin Inhalation Formulation and Characterisation
Type Original PaperSimvastatin SV a drug of the statin class currently used orally as an anticholesterolemic via the inhibition of the 3hydroxy3methylglutarylCoenzyme A HMGCoA reductase has been found...
View ArticleEsperion Therapeutics Provides ETC1002 Development Program Update; Reports...
Conference Call and Webcast Today Monday May 12 2014 at 430 p.m. Eastern Time Esperion Therapeutics Inc. NASDAQ ESPR a clinicalstage biopharmaceutical company focused on developing and commercializing...
View ArticleScientists reveal structural secrets of enzyme used to make popular...
University of California Los Angeles The cholesterollowering statin simvastatin first marketed as Zocor has generated billions of dollars in annual sales. UCLA scientists discovered in 2011 that a...
View ArticleEvolocumab Boosts LDL Reduction on Top of Statins
The LAPLACE2 study a trial adding evolocumab to moderate or intensive statin therapy that resulted in significant further reductions in LDL cholesterol levels is now published in JAMA. Heartwire
View ArticleAntibody combined with statin results in further reduction of cholesterol levels
Among patients with high cholesterol receiving moderate or highintensity statin therapy the addition of the human monoclonal antibody evolocumab resulted in additional lowering of lowdensity...
View ArticleJournal Of The American Medical Association Publishes Phase 3 LAPLACE2 Study...
THOUSAND OAKS Calif. May 13 2014 PRNewswire &160;Amgen NASDAQAMGN today announced the publication of data from the Phase 3 LAPLACE2 LDLC&160;Assessment...
View ArticleGSK's darapladib misses in Phase III ACS trial
GlaxoSmithKline plc LSEGSK; NYSEGSK said oncedaily oral darapladib SB480848 plus standard of care SOC missed the primary endpoint vs. placebo plus SOC in the Phase III SOLIDTIMI 52 trial to treat acute...
View Article